ATE429438T1 - Enzym katalisierte therapeutische aktivierung - Google Patents

Enzym katalisierte therapeutische aktivierung

Info

Publication number
ATE429438T1
ATE429438T1 AT00948886T AT00948886T ATE429438T1 AT E429438 T1 ATE429438 T1 AT E429438T1 AT 00948886 T AT00948886 T AT 00948886T AT 00948886 T AT00948886 T AT 00948886T AT E429438 T1 ATE429438 T1 AT E429438T1
Authority
AT
Austria
Prior art keywords
enzyme
cell
target enzyme
target
subject
Prior art date
Application number
AT00948886T
Other languages
English (en)
Inventor
H Shepard
Ming Chan
Michael Groziak
Original Assignee
Celmed Oncology Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celmed Oncology Usa Inc filed Critical Celmed Oncology Usa Inc
Application granted granted Critical
Publication of ATE429438T1 publication Critical patent/ATE429438T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/556—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells enzyme catalyzed therapeutic agent [ECTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01045—Thymidylate synthase (2.1.1.45)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91005—Transferases (2.) transferring one-carbon groups (2.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00948886T 1999-07-22 2000-07-21 Enzym katalisierte therapeutische aktivierung ATE429438T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14535699P 1999-07-22 1999-07-22
US14543799P 1999-07-23 1999-07-23
US19131500P 2000-03-21 2000-03-21
PCT/US2000/020008 WO2001007454A1 (en) 1999-07-22 2000-07-21 Enzyme catalyzed therapeutic activation

Publications (1)

Publication Number Publication Date
ATE429438T1 true ATE429438T1 (de) 2009-05-15

Family

ID=27386252

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00948886T ATE429438T1 (de) 1999-07-22 2000-07-21 Enzym katalisierte therapeutische aktivierung

Country Status (13)

Country Link
EP (1) EP1200455B1 (de)
JP (1) JP4982019B2 (de)
KR (1) KR20020092896A (de)
CN (1) CN1390227A (de)
AT (1) ATE429438T1 (de)
AU (1) AU775601B2 (de)
BR (1) BR0012677A (de)
CA (1) CA2379988C (de)
DE (1) DE60042073D1 (de)
HK (1) HK1053126A1 (de)
IL (1) IL147750A0 (de)
MX (1) MXPA02000763A (de)
WO (1) WO2001007454A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9708611D0 (en) * 1997-04-28 1997-06-18 Univ Cardiff Chemical compounds
US6703374B1 (en) 1997-10-30 2004-03-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleosides for imaging and treatment applications
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
JP2002500880A (ja) * 1998-01-23 2002-01-15 ニューバイオティックス インコーポレイテッド 酵素に触媒される治療剤
WO2001007088A2 (en) * 1999-07-22 2001-02-01 Newbiotics, Inc. Methods for treating therapy-resistant tumors
US6683061B1 (en) * 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
GB0009486D0 (en) 2000-04-17 2000-06-07 Univ Cardiff Chemical compounds
WO2002007780A2 (en) * 2000-07-20 2002-01-31 Newbiotics, Inc. Methods for identifying therapeutic targets
CA2441350A1 (en) 2001-01-19 2002-07-25 Newbiotics, Inc. Methods to treat autoimmune and inflammatory conditions
US7163923B2 (en) 2001-05-09 2007-01-16 Celmed Oncology (Usa), Inc. Peptide deformylase activated prodrugs
US7001922B2 (en) 2002-11-14 2006-02-21 Celmed Oncology (Usa), Inc. Peptide deformylase activated prodrugs
WO2004111192A2 (en) 2003-05-29 2004-12-23 The Scripps Research Institute Targeted delivery to legumain-expressing cells
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
CA2589935A1 (en) * 2004-12-09 2006-06-15 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
GB0609178D0 (en) 2006-05-09 2006-06-21 Univ Cardiff Novel compounds
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
DE102008030091B4 (de) 2008-06-25 2011-03-03 Resprotect Gmbh Uracilderivate und deren Verwendung
MX339822B (es) 2011-03-01 2016-06-13 Nucana Biomed Ltd Derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento contra el cancer.
WO2013040492A2 (en) 2011-09-16 2013-03-21 Gilead Sciences, Inc. Methods for treating hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AR088463A1 (es) 2011-10-21 2014-06-11 Abbvie Inc Metodos para el tratamiento de hcv
CN104436197A (zh) 2011-10-21 2015-03-25 艾伯维公司 至少两种直接作用抗病毒剂的组合产品
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2950786B1 (de) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Kombinationsformulierung zweier antiviraler verbindungen
NZ716840A (en) 2013-08-27 2017-06-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
EP3757112B1 (de) 2014-06-25 2023-06-07 Nucana PLC Gemcitabine-prodrugs
AU2015278900B2 (en) 2014-06-25 2019-04-04 NuCana plc Formulation comprising a gemcitabine-prodrug
CN108431016A (zh) * 2015-11-16 2018-08-21 艾可瑞恩治疗公司 核酸前体药物
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CN108148098B (zh) * 2018-02-08 2020-10-27 南通大学 靶向癌细胞高水平ros的吉西他滨-芳香氮芥缀合物及其制备方法和医药用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2298681C (en) * 1997-08-08 2008-07-08 Newbiotics, Inc. Methods and compositions for overcoming resistance to biologic and chemotherapy
DK1027365T3 (da) * 1997-10-30 2005-05-30 Us Gov Health & Human Serv Antitumor-uridinanaloger
JP2002500880A (ja) * 1998-01-23 2002-01-15 ニューバイオティックス インコーポレイテッド 酵素に触媒される治療剤

Also Published As

Publication number Publication date
DE60042073D1 (de) 2009-06-04
JP4982019B2 (ja) 2012-07-25
JP2003505466A (ja) 2003-02-12
WO2001007454A1 (en) 2001-02-01
HK1053126A1 (zh) 2003-10-10
MXPA02000763A (es) 2002-08-12
CA2379988C (en) 2010-10-19
AU6231900A (en) 2001-02-13
EP1200455B1 (de) 2009-04-22
BR0012677A (pt) 2003-07-01
AU775601B2 (en) 2004-08-05
CA2379988A1 (en) 2001-02-01
CN1390227A (zh) 2003-01-08
EP1200455A1 (de) 2002-05-02
KR20020092896A (ko) 2002-12-12
IL147750A0 (en) 2002-08-14

Similar Documents

Publication Publication Date Title
ATE429438T1 (de) Enzym katalisierte therapeutische aktivierung
CY1108470T1 (el) Πεπτιδια και πεπτιδομιμητες που εχουν αντι-πολλαπλασιαστικη δραστικοτητα και/ή τα οποια ενισχυουν παραγοντες ή αγωγες που προκαλουν βλαβη στο dna
MY154869A (en) Composition for treating metabolic syndrome
CY1105788T1 (el) Χρηση του taci σαν παραγοντα καταπολεμησης ογκων
PL1682126T3 (pl) Podstawione benzazole i ich zastosowanie jako inhibitorów kinazy Raf
BRPI0616630B8 (pt) compostos de pirazol substituídos
DK1257259T3 (da) Keramiske partikler med kontrolleret frigørelse, sammensætninger deraf, fremgangsmåder til fremstilling samt anvendelser deraf
EP1575509A4 (de) Epha2 agonistische monoklonale antikörper und anwendungsverfahren dafür
MX366119B (es) Uso de un agente inhibidor de masp-2 para el tratamiento de condiciones renales mediadas por complemento dependiente de la masp-2.
SI1663242T1 (sl) 2,4-pirimidindiaminske spojine in uporabe kot antiproliferativna sredstva
NO20010228D0 (no) Farmasöytiske preparater omfattende 2-kinoloner
IS2882B (is) Samsetning epóþílonhliðstæðna og virkra efna til efnameðferðar til þess að meðhöndla frumufjölgunarsjúkdóma
DK550188D0 (da) Antigestagen- og antioestrogenvirksomme forbindelser til behandling af hormonafhaengige tumorer
DE602004015811D1 (de) Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
AU9016998A (en) Methods and compositions for overcoming resistance to biologic and chemotherapy
BR112022019769A2 (pt) Composições de rna que direcionam claudina-18.2
DE69925508D1 (de) Zelladhäsion- und entzündungshemmende immunosuppressive verbindungen
WO2004012746A3 (en) New uses for inhibitors of inosine monophosphate dehydrogenase
ATE444083T1 (de) Selektives targeting von apoptotischen zellen
WO2002039952A3 (en) Synergistic ecta compositions
MXPA03004209A (es) Composicion farmaceutica o cosmetica y uso de un inhbidor de proteina cinasa c con un inhibidor de metaloproteasas de la matriz para inhibir la migracion de celulas de langerhans.
PT977716E (pt) Utilizacao de alcoois como aditivos para rebocos e/ou argamassas
GB9708092D0 (en) Materials and methods relating to inhibiting the interaction of p53 and mdm2
PL1853292T3 (pl) Kompozycja farmaceutyczna, zawierająca związki glutationu i betalainy, do prewencji i do zwalczania raka
WO2007057440A3 (en) Improved methods of using phosphoantigen for the treatment of cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties